Oncolyze

Oncolyze

Early Stage

Biotech company aiming to treat cancer by exploding cancer cells

Biotech company aiming to treat cancer by exploding cancer cells

Overview

Raised this Round: Raised: $0

Total Commitments ($USD)

Platform

SeedInvest

Start Date

08/03/2022

Close Date

Not Provided

Min. Goal
$2,700,000
Max. Goal
$15,000,000
Min. Investment

$997

Security Type

Equity - Preferred

Series

Seed

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$3.21

Pre-Money Valuation

$30,000,000

Year Founded

2011

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

New York, New York

Business Type

Growth

Oncolyze, with a valuation of $30 million, is raising funds on SeedInvest through Reg A+ crowdfunding. It is a biotech company aiming to treat cancer by exploding cancer cells. The first target demographic of Oncolyze is Acute Myelogenous Leukemia (AML), and its lead drug candidate, OM-301, has generated positive results in treating AML. Oncolyze has successfully completed in vitro and in vivo experiments and significantly increases survival rates. OM-301 has also received Orphan Drug Designation from the FDA. Steven J. Evans founded Oncolyze in 2011. The current crowdfunding campaign has a maximum target of $15,000,000. The campaign proceeds will be used for pre-clinical and manufacturing, financing, personnel, and clinical trials.

Balance Sheet

Cash and Cash Equivalents

$179,244

Total Assets

$272,780

Accounts Payable & Accrued Liabilities

$300,706

Long Term Debt

$0

Total Liabilities

$1,825,924

Total Stockholders' Equity

$-1,553,144

Total Liabilities and Equity

$272,780

Statement of Comprehensive Income Information

Costs & Expenses Applicable to Rev

$737,574

Net Income

$-740,574

Earnings Per Share - Basic

$-585.43

Earnings Per Share - Diluted

$-585.43

Auditor: Fruci & Associates
Financials as of: 08/03/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Oncolyze 02/07/2024 StartEngine $29,990,000 $766,168 Equity - Preferred Funded RegA+
Oncolyze 02/09/2023 SeedInvest $30,000,000 $0 Equity - Preferred Not Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Oncolyze on SeedInvest 2022
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $30,000,000
Price per Share: $3.21

Follow company

Follow Oncolyze on SeedInvest 2022

Buy Oncolyze's Deal Report

Warning: according to the close date for this deal, Oncolyze may no longer be accepting investments.

Oncolyze Deal Report

Get KingsCrowd’s comprehensive report on Oncolyze including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Oncolyze is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Oncolyze deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge